MICB and breast cancer: Among all 21 NK-activating ligands, only CD27 was associated with longer RFS in both lymph node negative and positive BC patients (Table 3) while three ligands (AICL, MICB and SLAMF6) were associated with longer RFS specifically in lymph node positive BC patients but not in lymph node negative patients (Table 3).